Concerning the previously published letter to the editor:
The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?
L. Van den Hove, Belg J Med Oncol 2013;7(1):3–7
(BELG J MED ONCOL 2013;7(3):72–73)
By: A. Hugo MD
Concerning the previously published letter to the editor:
The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?
L. Van den Hove, Belg J Med Oncol 2013;7(1):3–7
(BELG J MED ONCOL 2013;7(3):72–73)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
